New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

For a patient with lenalidomide-refractory R/R multiple myeloma at first or second relapse, how would MeziKd (if approved based on SUCCESSOR-2) factor into your sequencing decision relative to BCMA-directed and other available options?

Dimopoulos et al. PMID: 42289183
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester
Answered on

There is never a good time to be a myeloma patient, but this is the best time it has ever been.

Tldr; I would still prefer a BCMA-directed strategy for patients with BCMA-naive relapsed MM.

The recently reported results of the phase 3 SUCCESSOR-2 trial demonstrated the efficacy of mezigdomide, a novel CELMoD agent, in combination with carfilzomib and dexamethasone (MeziKd) compared with carfilzomib and dexamethasone alone (Kd) in patients with multiple myeloma who had received at least one prior line of therapy, including lenalidomide and an anti-CD38 monoclonal antibody. (Richardson et al., ASCO 2026)

The analysis included 479 heavily pretreated multiple myeloma patients (288 MeziKd, 191 Kd; median age 68 years, 25.1% ≥75 years), most of whom...

Join for free or sign in to see the full answer